HIV vaccine with treatment break to boost immune response
Part of Infections clinical trials.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–60 and able to give informed consent
- HIV-positive with lowest CD4 count historically between 250–450 cells/mm³, and current CD4 count above 450
- On stable HIV medications for at least 48 weeks with undetectable viral load (<50 copies/mL) for at least 48 weeks
- No history of serious HIV-related infections or cancers (except recurrent pneumonia)
- Willing to temporarily stop HIV medications under close monitoring and use condoms during that time
- Good overall health: normal blood counts, liver and kidney function; no active hepatitis B or C, heart disease, diabetes (except well-controlled type 2), or severe allergies to vaccines or vaccine ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.